Compugen Ltd. in brief
Compugen Ltd. is a listed company in the Biotechnology industry, based in Israel. It was founded in 1993. Its last known market value was $174 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $73 M and a net profit of $35 M, about 49 cents of profit for every dollar of sales. Its largest business segments by sales in 2025 were Single Operating (100%). Its shares trade under the symbol CGEN.TA (Tel Aviv).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Compugen Ltd.
Compugen Ltd. (Hebrew: קומפיוג'ן) is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Compugen Ltd. timeline
- 1993
- 🏁· approximateFounded
- 2000
- 🔔· approximateInitial public offering on Tel Aviv
Events of Compugen Ltd. from Wikidata and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #113 (Jan 2020) · #60 (Jan 2021) · #180 (Jan 2022) · #281 (Dec 2022) · #254 (Jul 2023) · #199 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- —
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- 48.6%
- Operating margin
- 43.1%
- Return on equity
- 34.4%
- Liabilities / assets
- 34.4%
- Revenue growth
- +161.2%
- R&D / revenue
- 31.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $73M | +161.2% | $31M | $35M | 48.6% |
| Dec 2024 | $28M | -16.7% | $-15M | $-14M | -51.1% |
| Dec 2023 | $33M | +346.1% | $-13M | $-19M | -56.0% |
| Dec 2022 | $8M | +25.0% | $-35M | $-34M | -449.2% |
| Dec 2021 | $6M | +200.0% | $-35M | $-34M | -570.0% |
| Dec 2020 | $2M | — | $-32M | $-30M | -1485.0% |
| Dec 2019 | — | — | $-29M | $-27M | — |
| Dec 2018 | $18M | — | $-23M | $-23M | -127.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $32M | $0M | $31M | $0.38 | — |
| Dec 2024 | $50M | $0M | $49M | $-0.16 | — |
| Dec 2023 | $-36M | $0M | $-36M | $-0.21 | — |
| Dec 2022 | $-34M | $0M | $-35M | $-0.39 | — |
| Dec 2021 | $-23M | $0M | $-23M | $-0.41 | — |
| Dec 2020 | $-28M | $0M | $-28M | $-0.37 | — |
| Dec 2019 | $-28M | $0M | $-28M | $-0.43 | — |
| Dec 2018 | $-13M | $0M | $-13M | $-0.41 | — |
SEC filings
- Nov 9, 20266-KReport of foreign issuer
- Sep 10, 20266-KReport of foreign issuer
- Aug 3, 20266-KReport of foreign issuer
- Aug 3, 20266-KReport of foreign issuer
- May 18, 20266-KReport of foreign issuer
- Mar 2, 202620-FAnnual report (foreign issuer) · period to Dec 2025
- Mar 2, 20266-KReport of foreign issuer
- Feb 12, 20266-KReport of foreign issuer
- Dec 17, 20256-KReport of foreign issuer
- Nov 10, 20256-KReport of foreign issuer
- Oct 14, 20256-KReport of foreign issuer
- Sep 17, 20256-KReport of foreign issuer
Official filings of Compugen Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $73 M
- Operating income
- $31 M
- Net income
- $35 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $157 M
- Total liabilities
- $54 M
- Total equity
- $103 M
As of December-2025
Mutual funds holding Compugen Ltd.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 1.02 M | $2 M | — | 0.29% | no change | Jun 30, 2026 |
| 🇺🇸 ARK Israel Innovative Technology ETFARK Investment Management LLC | 887,867 | $2 M | — | 1.5% | +13% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc. | 346,188 | $1 M | — | <0.01% | −0.1% | Jun 30, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 71,228 | $0 M | — | <0.01% | +2.5% | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 56,738 | $0 M | — | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 63,080 | $0 M | — | 0.02% | +1.0% | Jun 30, 2026 |
| 🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP | 19,304 | $0 M | — | <0.01% | −25% | Jul 31, 2026 |
| 🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP | 18,907 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP | 16,001 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 14,192 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP | 13,486 | $0 M | — | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 10,412 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP | 8,383 | $0 M | — | <0.01% | +130% | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 4,200 | $0 M | — | <0.01% | −11% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 14 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Compugen Ltd.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Savitzky Kinneret LivnatDirector | Grant or award | +7,500 | — | —local | 20,850 | Form 4 |
| filed | Gilead HalevyDirector | Grant or award | +7,500 | — | —local | 18,907 | Form 4 |
| filed | Michelle MahlerChief Medical Officer | Grant or award | +13,500 | — | —local | 36,625 | Form 4 |
| filed | Sanford S. ZweifachDirector | Grant or award | +7,500 | — | —local | 20,180 | Form 4 |
| filed | Zurit LevineSVP, Business Development | Grant or award | +18,000 | — | —local | 47,375 | Form 4 |
| filed | Mathias HukkelhovenDirector | Grant or award | +7,500 | — | —local | 17,500 | Form 4 |
| filed | David SilbermanChief Financial Officer | Grant or award | +19,500 | — | —local | 55,000 | Form 4 |
| filed | Eran PerryDirector | Grant or award | +7,500 | — | —local | 17,500 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars
Markets and events: Compugen Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 158 shares at $2.12
- : 463 shares at $2.14
- : 12,221 shares at $2.34
- : 4,548 shares at $2.38
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Compugen Ltd. scorecard#
Passes 11 of the 14 checks that could be worked out: strongest in growth (6 of 6), weakest in profitability (4 of 5). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth6 of 6
- ✓Revenue grew in the newest year161.2%Revenue up 161.2% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years113.3%113.3% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median113.3%113.3% a year against Biotechnology's median of 12.9% (181 companies).
- ✓Earnings per share grew in the newest year0.38 vs -0.16Diluted EPS 0.38 in fiscal 2025 against -0.16 the year before (report's currency).
- ✓Net income higher than five years earlier$35 M$35 M in fiscal 2025 against -$30 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability4 of 5
- ✓Profitable in the newest year$35 MNet income $35 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median43.1%43.1% against Biotechnology's median of -60.5% (243 companies).
- ✓Return on equity above 15%44.8%44.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier43.1%43.1% in fiscal 2025 against -471.6% in 2022.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities6.6×Current ratio 6.56 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year4.8%Diluted shares up 4.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Compugen Ltd.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 43.1% | -60.5% | |
| Net margin | 48.6% | -68.9% | |
| Return on equity | 44.8% | -61.0% | |
| Revenue growth, 3 years a year | 113.3% | 12.9% | |
| Revenue growth | 161.2% | 15.8% | |
| Free cash flow margin | 43.1% | -61.5% |
6of 8on the Piotroski tests of financial strength
Compugen Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 73+161%100% | 28−16.7%100% | 33+346%100% | 7.5+25.0%100% | 6.0+200%100% | 2.0—100% | — | 18—100% | — | 0.7—100% | |
| Cost of revenue | 9.3+16.7%12.7% | 7.9+296%28.5% | 2.0+106%6.0% | 1.0+43.4%13.0% | 0.7+1033%11.3% | 0.1—3.0% | — | 1.0—5.8% | — | 0.2—31.3% | |
| Gross profit | 64+219%87.3% | 20−36.6%71.5% | 31+382%94.0% | 6.5+22.7%87.0% | 5.3+174%88.7% | 1.9—97.0% | — | 17—94.2% | — | 0.5—68.7% | |
| Research and development | 23−8.3%31.3% | 25−28.0%89.0% | 34+12.5%103% | 31+6.8%409% | 29+26.1%478% | 23+14.9%1138% | 20−34.6%— | 30+6.1%170% | 29+16.4%— | 25—3448% | |
| Selling and marketing | — | — | — | — | — | 0—0.0% | 0−100%— | 0.3—1.8% | 0—— | 0—0.0% | |
| General and administrative | 8.9−5.8%12.2% | 9.4−3.0%33.9% | 9.7−5.7%29.1% | 10−5.0%138% | 11+10.7%181% | 9.8+16.6%490% | 8.4+4.6%— | 8.0+5.3%45.2% | 7.6+3.9%— | 7.3—1032% | |
| Operating expenses | 32−7.6%44.2% | 35−21.6%125% | 44+6.1%133% | 42+3.7%559% | 40+20.8%673% | 33+15.8%1672% | 29−27.8%— | 40+6.9%225% | 37+13.1%— | 33—4645% | |
| Operating income | 31—43.1% | −15—−53.4% | −13—−38.8% | −35—−472% | −35—−585% | −31—−1575% | −29—— | −23—−130% | −37—— | −33—−4576% | |
| Interest and finance income | 3.9+11.9%5.4% | 3.5+17.9%12.5% | 3.0+106%8.8% | 1.4+60.7%19.2% | 0.9−49.3%14.9% | 1.8+88.8%88.3% | 0.9+45.4%— | 0.6+22.9%3.6% | 0.5−28.2%— | 0.7—102% | |
| Income before tax | 35—48.6% | −9.7—−34.8% | −9.8—−29.2% | −34—−448% | −34—−570% | −30—−1485% | −28—— | −23—−127% | −37—— | −31—−4422% | |
| Income tax | 0.1−98.8%0.1% | 4.5−49.6%16.2% | 9.0+15366%26.8% | 0.1—0.8% | 0—0.0% | 0—0.0% | −0.7—— | — | — | 0.0—2.8% | |
| Net income attributable to shareholders | 35—48.6% | −14—−51.1% | −19—−56.1% | −34—−449% | −34—−570% | −30—−1485% | −27—— | −23—−127% | −37—— | −32—−4425% | |
| Earnings per share, basic | 0.38—— | -0.16—— | -0.21—— | -0.39—— | -0.41—— | -0.37—— | -0.43—— | -0.41—— | -0.72—— | -0.62—— | |
| Earnings per share, diluted | 0.38—— | -0.16—— | -0.21—— | -0.39—— | -0.41—— | -0.37—— | -0.43—— | -0.41—— | -0.72—— | -0.62—— | |
| Shares, weighted average (basic) | 93+4.4%— | 90+2.2%— | 88+1.2%— | 87+2.8%— | 84+5.8%— | 80+25.1%— | 64+15.1%— | 55+8.0%— | 51+0.6%— | 51—— | |
| Shares, weighted average (diluted) | 94+4.8%— | 90+2.2%— | 88+1.2%— | 87+2.8%— | 84+5.8%— | 80+25.1%— | 64+15.1%— | 55+8.0%— | 51+0.6%— | 51—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 91+397%57.9% | 18+31.2%15.9% | 14+25.6%11.4% | 11+41.8%11.7% | 7.8+9.2%5.9% | 7.1−22.2%5.2% | 9.2+56.7%17.1% | 5.9−77.0%11.0% | 25+162%65.7% | 9.7—13.6% | |
| Short-term investments | 9.3−60.7%5.9% | 24+101%20.5% | 12—9.7% | 0—0.0% | — | — | — | — | — | — | |
| Receivables | — | 0−100%0.0% | 61—50.3% | 0—0.0% | — | 2.0—1.4% | — | — | — | — | |
| Other current assets | 0.1+1.4%0.1% | 0.1−37.2%0.1% | 0.2−2.6%0.2% | 0.2+77.1%0.2% | 0.1+7.4%0.1% | 0.1−60.1%0.1% | 0.3+428%0.6% | 0.1−92.2%0.1% | 0.7−35.7%1.9% | 1.2—1.6% | |
| Current assets | 148+39.6%94.5% | 106−7.5%92.2% | 115+33.0%94.4% | 86−30.1%91.5% | 123−4.5%93.2% | 129+187%93.3% | 45−3.4%83.7% | 47+49.4%87.6% | 31−50.3%80.5% | 63—88.1% | |
| Property, plant and equipment | 0.7−20.1%0.4% | 0.9−29.9%0.7% | 1.2−20.6%1.0% | 1.5−7.6%1.6% | 1.7−3.1%1.3% | 1.7−26.8%1.2% | 2.3−30.7%4.3% | 3.4−27.4%6.3% | 4.6−22.1%12.0% | 6.0—8.4% | |
| Right-of-use (leased) assets | 2.5−11.3%1.6% | 2.8+114%2.5% | 1.3−27.2%1.1% | 1.8−18.7%1.9% | 2.2−18.9%1.7% | 2.8−14.6%2.0% | 3.2—6.0% | — | — | — | |
| Non-current assets | 8.5−5.0%5.5% | 9.0+33.2%7.8% | 6.8−16.1%5.6% | 8.1−10.0%8.5% | 8.9−3.1%6.8% | 9.2+5.3%6.7% | 8.8+32.7%16.3% | 6.6−12.8%12.4% | 7.6−10.5%19.5% | 8.5—11.9% | |
| Total assets | 157+36.2%100% | 115−5.2%100% | 121+28.8%100% | 94−28.7%100% | 132−4.4%100% | 138+157%100% | 54+1.1%100% | 53+37.3%100% | 39−45.5%100% | 71—100% | |
| Accounts payable | 2.4+28.0%1.5% | 1.8−47.5%1.6% | 3.5+97.5%2.9% | 1.8−61.6%1.9% | 4.6+227%3.5% | 1.4+29.9%1.0% | 1.1−63.1%2.0% | 2.9−14.5%5.5% | 3.4+170%8.9% | 1.3—1.8% | |
| Current liabilities | 23+12.0%14.4% | 20−23.2%17.5% | 26+120%21.6% | 12−30.3%12.7% | 17+62.5%12.9% | 11+54.3%7.6% | 6.8−31.7%12.7% | 10.0+61.3%18.8% | 6.2+30.7%16.0% | 4.7—6.7% | |
| Lease liabilities (non-current) | 2.4−1.0%1.6% | 2.5+243%2.1% | 0.7−45.2%0.6% | 1.3−33.8%1.4% | 2.0−21.6%1.5% | 2.5−15.1%1.8% | 3.0—5.5% | — | — | — | |
| Non-current liabilities | 31−21.7%20.0% | 40+35.3%34.7% | 30+545%24.3% | 4.6−45.3%4.9% | 8.4+4.5%6.3% | 8.0−7.1%5.8% | 8.6+45.0%16.0% | 5.9+82.7%11.2% | 3.3+13.0%8.4% | 2.9—4.0% | |
| Retained earnings | −453—−290% | −489—−425% | −475—−391% | −456—−484% | −422—−319% | −388—−280% | −358—−666% | −331—−622% | −308—−796% | −271—−381% | |
| Shareholders' equity | 103+87.1%65.6% | 55−16.2%47.8% | 66−15.6%54.0% | 78−27.2%82.5% | 107−10.9%80.7% | 120+213%86.6% | 38+2.9%71.3% | 37+27.1%70.0% | 29−53.9%75.6% | 64—89.3% | |
| Total liabilities and equity | 157+36.2%100% | 115−5.2%100% | 121+28.8%100% | 94−28.7%100% | 132−4.4%100% | 138+157%100% | 54+1.1%100% | 53+37.3%100% | 39−45.5%100% | 71—100% | |
| Shares outstanding | 95+5.6%— | 90+0.3%— | 89+3.0%— | 87+0.2%— | 86+3.3%— | 84+23.2%— | 68+13.5%— | 60+16.7%— | 51+0.3%— | 51—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 1.9−37.8%2.6% | 3.0−14.8%10.8% | 3.6−18.0%10.6% | 4.3+1.2%57.7% | 4.3+54.3%71.3% | 2.8+15.1%139% | 2.4+11.2%— | 2.2−17.7%12.2% | 2.6−14.6%— | 3.1—433% | |
| Cash from operating activities | 32−36.2%43.5% | 50—178% | −36—−107% | −34r−35—−455% | −23r−23—−378% | −28—−1416% | −28—— | −13—−74.7% | −31—— | −20—−2784% | |
| Capital expenditure | −0.3—−0.4% | −0.1—−0.4% | −0.2—−0.5% | −0.5—−6.4% | −0.3—−4.9% | −0.2—−8.3% | −0.2—— | −0.2—−0.9% | −0.4—— | −2.6—−365% | |
| Cash from investing activities | 30—41.2% | −46−230%−166% | 36−4.2%106% | 37+460%494% | 6.6—110% | −82−1642%−4109% | 5.3—— | −35−176%−198% | 46+185%— | 16r16—2277% | |
| Shares issued | 11+1837%14.5% | 0.5−82.3%2.0% | 3.1—9.2% | 0−100%0.0% | 15−79.8%249% | 74+226%3707% | 23−17.9%— | 28—156% | — | — | |
| Cash from financing activities | 11+1814%14.6% | 0.6−82.0%2.0% | 3.1+773%9.2% | 0.4−97.9%4.7% | 17−84.5%281% | 108+318%5423% | 26−8.7%— | 28+14027%160% | 0.2−91.8%— | 2.5—345% | |
| Exchange-rate effect on cash | 0.1+98.5%0.2% | 0.1−47.3%0.2% | 0.1—0.4% | −0.4—−5.2% | −0.1—−1.0% | — | — | — | — | — | |
| Change in cash | 72+1721%99.5% | 4.0+40.2%14.3% | 2.8−2.5%8.5% | 2.9+313%38.8% | 0.7—11.7% | — | — | — | 16—— | −1.2r−1.1—−162% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F/A | 20-F/A | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Compugen Ltd. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Single Operating$73 M100%+161%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Compugen Ltd. compares in Biotechnology
- Revenue$73 M · higher than 65% of 647
- Net margin48.6% · higher than 98% of 408
- Revenue growth161.2% · higher than 88% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Compugen Ltd.🇮🇱 | $174 M | — | 48.6% | +161.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Compugen Ltd.? Verify and update this profile — free
Show Compugen Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.